Intarcia Therapeutics \USA

A B2B2C platform that partners with Medicaid plans, correctional health systems, and nursing homes to deliver ultra-long-acting injectable medications (3-6 month duration) for chronic conditions via mobile nurse practitioners. Instead of building a new drug delivery device, leverage existing FDA-approved long-acting injectables (LAIs) for schizophrenia, HIV PrEP, contraception, and addiction treatment—medications where adherence failure has catastrophic consequences and where the target populations have structural barriers to pharmacy access. The business model is a per-member-per-month (PMPM) fee paid by institutions to guarantee medication adherence for high-risk populations. SteadyScript handles: (1) mobile nurse dispatch for in-home or in-facility injections, (2) medication procurement and cold chain logistics, (3) adherence tracking and reporting to payers, and (4) care coordination with primary care providers. The wedge is correctional health systems, where medication adherence is a major cost driver (inmates released without meds have 70% recidivism to emergency departments within 30 days). Unlike Intarcia, this doesn't require inventing new technology or navigating device approvals—it's a logistics and care delivery play using existing approved medications. The margin comes from reducing downstream costs (hospitalizations, incarcerations, disease progression) that payers are already paying for.